Excessive Weight Gain Associated with Dolutegravir Initiation in a 10-Year-Old Female with Perinatally Acquired Human Immunodeficiency Virus: A Case Report and Review of the Literature

Children with perinatally acquired human immunodeficiency virus (PHIV) face a lifetime of combination antiretroviral treatment that often includes dolutegravir (DTG). DTG, an integrase strand inhibitor that has been linked to weight gain in adults, is increasingly being used in children. Understanding its potential short- and long-term sequelae in children is critically important. We report a case of excessive weight gain in a child with PHIV on DTG and provide a brief literature review.